Livija Bardina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Livija Bardina has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Bianca M. de Graaf
Department of Clinical Genetics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
2 shared publications - Daphne J. Smits
Department of Clinical Genetics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
2 shared publications - Dmitrijs Rots
Department of Clinical Genetics, Erasmus MC, Rotterdam, The Netherlands
2 shared publications - Federico Ferraro
Division of Cardiovascular Medicine, Department of Medicine, Stanford University , Stanford, CA 94305
2 shared publications - Laura Donker Kaat
Erasmus University Medical Centre
2 shared publications - Mark Drost
Department of Clinical Genetics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
2 shared publications
Latest Publications
- Open Access
- 20 October 2025
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 34 (1) , 108-118
Nanopore long-read sequencing for the critically ill facilitates ultrarapid diagnostics and urgent clinical decision making
Critically ill pediatric patients often have genetic disorders requiring a rapid diagnosis to guide urgent care decisions. Standard genetic testing typically takes weeks and requires multiple tests. Nanopore long-read genome sequencing (LR-GS) delivers genome-wide results within days as a one-test-fits-all solution. As one of the first centers in Europe, we implement ultrarapid LR-GS for critically ill patients. We enrolled 26 critically ill patients (median age 2 months) suspected of having a genetic disorder at the intensive care unit to perform (ultra)rapid nanopore LR-GS alongside standard genomic care. We compared diagnostic yield, turnaround time (TAT), and evaluated the impact on clinical decision making. In 11/26 cases a genetic diagnosis was made with (ultra)rapid LR-GS. From sample receipt to result, the average TAT was 5.3 days (range 2.0–10.8) for LR-GS and 18.4 days (range 6.1–29.1) for standard genomic care. DNA methylation analysis from LR-GS expedited the diagnosis in 3/26 cases. In 7/11 solved cases ultrarapid LR-GS led to immediate adjustments in patient care, e.g., medication switch or termination of treatment. Our findings underscore the clinical impact of ultrarapid LR-GS, including added value of methylation analysis, for critically ill patients and highlight existing challenges, paving the way to ultrarapid LR-GS integration into standard diagnostics.
- 20 October 2025
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 34 (1) , 108-118
Open AccessNanopore long-read sequencing for the critically ill facilitates ultrarapid diagnostics and urgent clinical decision making
Critically ill pediatric patients often have genetic disorders requiring a rapid diagnosis to guide urgent care decisions. Standard genetic testing typically takes weeks and requires multiple tests. Nanopore long-read genome sequencing (LR-GS) delivers genome-wide results within days as a one-test-fits-all solution. As one of the first centers in Europe, we implement ultrarapid LR-GS for critically ill patients. We enrolled 26 critically ill patients (median age 2 months) suspected of having a genetic disorder at the intensive care unit to perform (ultra)rapid nanopore LR-GS alongside standard genomic care. We compared diagnostic yield, turnaround time (TAT), and evaluated the impact on clinical decision making. In 11/26 cases a genetic diagnosis was made with (ultra)rapid LR-GS. From sample receipt to result, the average TAT was 5.3 days (range 2.0–10.8) for LR-GS and 18.4 days (range 6.1–29.1) for standard genomic care. DNA methylation analysis from LR-GS expedited the diagnosis in 3/26 cases. In 7/11 solved cases ultrarapid LR-GS led to immediate adjustments in patient care, e.g., medication switch or termination of treatment. Our findings underscore the clinical impact of ultrarapid LR-GS, including added value of methylation analysis, for critically ill patients and highlight existing challenges, paving the way to ultrarapid LR-GS integration into standard diagnostics.
- Open Access
Synthetic epigenomes for open cross-platform episignature classifiers
DNA methylation (DNAm) signature (episignature) classifiers support diagnosis of rare diseases. Yet episignature testing is confined to a dedicated array platform, and most classifiers are neither openly available nor fully reproducible. Laboratories cannot train their own classifiers as positive controls are scarce and cannot be shared under privacy regulations. Here, we develop and release MethaDory, a framework to train episignature classifiers using synthetic DNAm profiles generated in silico from control data and summary statistics of affected individuals from any platform of interest. We trained 188 classifiers spanning 102 rare disorders and validated 154 across 915 individuals with an episignature-associated diagnosis, 533 healthy controls profiled with DNAm arrays, Oxford Nanopore, and PacBio sequencing, together with 7 international centres. MethaDory achieved an average F1 0.9 on arrays, matching or outperforming existing approaches. We show MethaDory classifier application to long-read genome data, facilitating diagnoses in unsolved cases and in ultra-rapid diagnostic settings.
Open AccessSynthetic epigenomes for open cross-platform episignature classifiers
DNA methylation (DNAm) signature (episignature) classifiers support diagnosis of rare diseases. Yet episignature testing is confined to a dedicated array platform, and most classifiers are neither openly available nor fully reproducible. Laboratories cannot train their own classifiers as positive controls are scarce and cannot be shared under privacy regulations. Here, we develop and release MethaDory, a framework to train episignature classifiers using synthetic DNAm profiles generated in silico from control data and summary statistics of affected individuals from any platform of interest. We trained 188 classifiers spanning 102 rare disorders and validated 154 across 915 individuals with an episignature-associated diagnosis, 533 healthy controls profiled with DNAm arrays, Oxford Nanopore, and PacBio sequencing, together with 7 international centres. MethaDory achieved an average F1 0.9 on arrays, matching or outperforming existing approaches. We show MethaDory classifier application to long-read genome data, facilitating diagnoses in unsolved cases and in ultra-rapid diagnostic settings.